
    
      This is an open-label, multicenter study conducted in up to 10 sites in the United States. A
      total of 13 pediatric male or female patients age ≥12 to <17 years will be enrolled. The
      patients will administer a dose of Rectiv® twice daily to characterize the safety,
      pharmacokinetics , and exploratory efficacy of Nitroglycerin Ointment 0.4% (RECTIV® )over 5
      days
    
  